JP2009526087A - 悪液質の予防および処置のための組成物および方法 - Google Patents

悪液質の予防および処置のための組成物および方法 Download PDF

Info

Publication number
JP2009526087A
JP2009526087A JP2008555886A JP2008555886A JP2009526087A JP 2009526087 A JP2009526087 A JP 2009526087A JP 2008555886 A JP2008555886 A JP 2008555886A JP 2008555886 A JP2008555886 A JP 2008555886A JP 2009526087 A JP2009526087 A JP 2009526087A
Authority
JP
Japan
Prior art keywords
day
roxithromycin
agonist
macrolide
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008555886A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009526087A5 (enExample
Inventor
リチャード ケンリー,
ジョナス イクブロム,
ミハイル デニセンコ,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2009526087A publication Critical patent/JP2009526087A/ja
Publication of JP2009526087A5 publication Critical patent/JP2009526087A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008555886A 2005-12-22 2006-12-20 悪液質の予防および処置のための組成物および方法 Withdrawn JP2009526087A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75311805P 2005-12-22 2005-12-22
US77275206P 2006-02-13 2006-02-13
PCT/IB2006/004315 WO2008093148A2 (en) 2005-12-22 2006-12-20 Compositions and methods for prevention and treatment of cachexia

Publications (2)

Publication Number Publication Date
JP2009526087A true JP2009526087A (ja) 2009-07-16
JP2009526087A5 JP2009526087A5 (enExample) 2010-01-07

Family

ID=38194678

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008555886A Withdrawn JP2009526087A (ja) 2005-12-22 2006-12-20 悪液質の予防および処置のための組成物および方法

Country Status (6)

Country Link
US (1) US8080528B2 (enExample)
EP (1) EP1991270A4 (enExample)
JP (1) JP2009526087A (enExample)
MX (1) MX2008007790A (enExample)
NO (1) NO20083240L (enExample)
WO (1) WO2008093148A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021509A2 (en) * 1998-10-15 2000-04-20 Imperial College Innovations Limited Methods of treatment
GB0624282D0 (en) 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
EP2155180B1 (en) * 2007-04-24 2016-07-13 Acacia Pharma Limited Drug combination and its use in the treatment of muscle loss
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
ES2721753T3 (es) 2007-05-21 2019-08-05 Alderbio Holdings Llc Anticuerpos contra IL-6 y usos de los mismos
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US20090221518A1 (en) * 2007-11-18 2009-09-03 Anaborex, Inc. Compositions and Methods for Treatment of Exudative Serous Effusion
US8257684B2 (en) * 2008-03-26 2012-09-04 Neurosigma, Inc. Methods for identifying and targeting autonomic brain regions
JP5620918B2 (ja) * 2008-11-25 2014-11-05 ブリストル・マイヤーズ スクイブ カンパニー アルブミンを上昇および/またはcrpを低下させるためのil−6アンタゴニスト
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
WO2011066371A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2012009542A2 (en) * 2010-07-14 2012-01-19 Kansas State University Research Foundation Methods for alleviating chronic pain and improving performance of cattle undergoing dehorning or castration
WO2012071561A2 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
JP2015512902A (ja) * 2012-03-28 2015-04-30 アフィボディ・アーベー 経口投与
WO2020018554A1 (en) * 2018-07-17 2020-01-23 The Regents Of The University Of California Methods of treating renal disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859782A (en) * 1986-06-26 1989-08-22 Harbor Branch Oceanographic Institution, Inc. Misakinolide compositions and their derivatives
EP0662324A1 (en) 1987-09-15 1995-07-12 The Rowett Research Institute Use of beta-adrenergic agonists for treating loss of function of striated muscles
HUT50044A (en) 1988-04-12 1989-12-28 Bristol Myers Co Process for producing pharmaceutical composition comprising megestrol acetate as active ingredient
US5252564A (en) * 1991-03-29 1993-10-12 The United States Of America As Represented By The Secretary Of Agriculture Method to decrease cortisol secretion by feeding melengesterol acetate
CA2194049A1 (en) * 1994-06-28 1996-01-11 Georgi Stankov Novel clinical uses of polyene macrolides
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US6706892B1 (en) * 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US7211568B2 (en) 2003-12-18 2007-05-01 Kosan Biosciences Incorporated 9-Desoxoerythromycin compounds as prokinetic agents
WO2008004224A2 (en) 2006-07-03 2008-01-10 Arie Levine Synergistic compositions for crohn's disease and inflammatory gastrointestinal disorders

Also Published As

Publication number Publication date
US20070149465A1 (en) 2007-06-28
EP1991270A4 (en) 2009-12-02
WO2008093148A3 (en) 2009-04-16
EP1991270A2 (en) 2008-11-19
NO20083240L (no) 2008-09-22
MX2008007790A (es) 2009-03-04
WO2008093148A2 (en) 2008-08-07
US8080528B2 (en) 2011-12-20

Similar Documents

Publication Publication Date Title
US8080528B2 (en) Compositions and methods for treatment of cachexia
WO2007095497A2 (en) Compositions and methods for prevention and treatment of cachexia
TWI874339B (zh) 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式
US20220265682A1 (en) Drug composition containing abiraterone acetate, and preparation method therefor and application thereof
US8529952B2 (en) Pharmaceutical composition containing fenofibrate and method for the preparation thereof
US10155006B2 (en) Combination therapies and methods of use thereof for treating cancer
JP6472063B2 (ja) 少なくとも1つの炎症性要素を呈する腸管疾患を治療するための方法
CN116096373A (zh) 用于治疗先天性肾上腺增生症的crf1受体拮抗剂
WO2008122190A1 (en) The composition comprising l-carnitine or derivatives thereof and its use
MX2008007786A (es) Dispositivo para convertir energia termica en energia electrica.
RU2586742C2 (ru) Композиция для лечения метаболических расстройств
JP6371379B2 (ja) ヒドロコルチゾンを含有する組成物
JP2017200942A (ja) 副腎機能障害の治療
TW200840590A (en) Compositions and methods for prevention and treatment of cachexia
EP3908260B1 (en) Pharmaceutical composition for reducing protein bound uremic toxins
US20250152533A1 (en) Novel Beta-Alanine Compositions and Methods of Use Thereof
US20210205333A1 (en) Methods and compositions for treating 25-hydroxyvitamin d deficiency
JP2025026576A (ja) 先天性副腎過形成を処置するためのcrf1受容体アンタゴニスト、その医薬製剤および固体形態
HK40005336B (zh) 包含美金刚和褪黑素的组合的药物组合物
HK1084895B (en) Pharmaceutical composition containing fenofibrate and method for the preparation thereof

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091110

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20110315

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20110405